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in controlling olanzapine-induced weight gain. In the presentstudy, we investigate whether co-23 treatment with betahistine is able to prevent dyslipidemia induced by chronic olanzapine 24 treatment and the underlying mechanisms. Female rats were orally administered with olanzapine
25
(1 mg/kg, t.i.d.) for 3.5 consecutive weeks and then a 2.5-week drug withdrawal. Then, rats were 
66
Overthe lastfew decades, weight gain and other metabolic disorders caused by SGAs have 67 attractedincreasing attention [4, 5] .Dyslipidemia is one of the troublesome side-effects associated 68 with chronic antipsychotic medication, which may further causecardiovascular disease, stroke,
69
and premature death [6, 7] . (Fig.1) , for the first 3.5 weeks, 48 rats were divided into two groups: half 150 of them (n=24) were treated with olanzapine (1 mg/kg, Eli Lilly, Indianapolis, USA, t.i.d.), and 151 the other half were treated with vehicle. From week 3.5 to week 6, norats received any treatment 152 during this period (e.g. olanzapine was withdrawn). From week 6 to week 11, the two groups with western blot analysis.
Western blot analysis 225
Whole-protein lysates of liver tissue were extracted using 10% Nonidet P-40 lysis buffer 
Results

253
Body weight, adipose mass and energy intake data have been reported previously [25] . Briefly,
254
olanzapine-only rats displayed a significantly higher body weight gain, white adipose mass
255
(including inguinal, periovarian, mesentery and perirenal fat), food intake and feeding efficiency,
256
whereas the O+B co-treatment reversed weight gain, white fat mass, and feeding efficiency 257 compared with the olanzapine-onlytreatmentgroup.
259
3.1Effects onlipid concentration in the liver and blood
260
As shown in Table 1 , plasma TG levels weresignificantly increased (1.06±0.11(C)vs. (Fig.2) . It should be 
286
( Fig. 2A-2D ). 
Discussion
358
The present study showed that chronic treatment with olanzapineled to a significant increase in 
492
Therefore, it is most likely that betahistine co-treatment is also effective to ameliorate 493 olanzapine-induced dyslipidemia in male rats, although future studyin male rat model is 494 necessary.
496
Conclusion
497
This study provided further evidence that chronic olanzapine induces accumulation of hepatic 498 lipid. More importantly,co-treatment with betahistine appears to be effective inameliorating olanzapine-induced dyslipidemia through modulation of the AMPKα-SREBP-1and PPARα-500 dependent pathways (Fig. 6) . A great deal of further work needs to be carried out to delineate not 501 only the precise molecular mechanisms by which betahistine activates AMPKα to regulate 502 lipolysis, but also the signalling pathways that link hepatic H1R with AMPKα. Furthermore,
503
clinicaltrials have shown that short-term betahistine co-treatment produces a clinically significant 
